{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:26:31Z","timestamp":1769250391676,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009332","name":"Mag-Tarmfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009332","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10620-022-07630-5","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T02:02:36Z","timestamp":1661133756000},"page":"608-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti-Saccharomyces cerevisiae Antibodies Are Only Modestly More Common in Subjects Later Developing Crohn's Disease"],"prefix":"10.1007","volume":"68","author":[{"given":"L.","family":"Bodecker-Zingmark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Widbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hultdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-0118","authenticated-orcid":false,"given":"P.","family":"Karling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"issue":"Suppl 3","key":"7630_CR1","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013s106.","journal-title":"Gut."},{"issue":"1","key":"7630_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/apt.12528","volume":"39","author":"K Busch","year":"2014","unstructured":"Busch K, Ludvigsson JF, Ekstrom-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39:57\u201368.","journal-title":"Aliment Pharmacol Ther."},{"issue":"27","key":"7630_CR3","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020;383:2652\u20132664.","journal-title":"N Engl J Med."},{"issue":"2","key":"7630_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1128\/cdli.3.2.219-226.1996","volume":"3","author":"B Sendid","year":"1996","unstructured":"Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A et al. Specific antibody response to oligomannosidic epitopes in Crohn\u2019s disease. Clin Diagn Lab Immun. 1996;3:219\u2013226.","journal-title":"Clin Diagn Lab Immun."},{"issue":"6","key":"7630_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/gut.42.6.788","volume":"42","author":"JF Quinton","year":"1998","unstructured":"Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788\u2013791.","journal-title":"Gut."},{"issue":"3","key":"7630_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1365-2249.2003.02392.x","volume":"135","author":"LJ Walker","year":"2004","unstructured":"Walker LJ, Aldhous MC, Drummond HE, Smith BRK, Nimmo ER, Arnott IDR et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn\u2019s disease are associated with disease severity but not NOD2\/CARD15 mutations. Clin Exp Immunol. 2004;135:490\u2013496.","journal-title":"Clin Exp Immunol."},{"issue":"7","key":"7630_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/ibd.21903","volume":"18","author":"L Prideaux","year":"2012","unstructured":"Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340\u20131355.","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"7630_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/gut.34.1.56","volume":"34","author":"E Peen","year":"1993","unstructured":"Peen E, Almer S, Bodemar G, Ryden BO, Sjolin C, Tejle K et al. Anti-Lactoferrin Antibodies and Other Types of Anca in Ulcerative-Colitis, Primary Sclerosing Cholangitis, and Crohns-Disease. Gut. 1993;34:56\u201362.","journal-title":"Gut."},{"issue":"3","key":"7630_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1572-0241.2007.01652.x","volume":"103","author":"M Papp","year":"2008","unstructured":"Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J et al. New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2\/CARD15 Genotype in a Hungarian IBD Cohort. American Journal of Gastroenterology. 2008;103:665\u2013681.","journal-title":"American Journal of Gastroenterology."},{"key":"7630_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00508-010-1344-y","volume":"122","author":"E Homsak","year":"2010","unstructured":"Homsak E, Micetic-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr. 2010;122:19\u201325.","journal-title":"Wien Klin Wochenschr."},{"issue":"4","key":"7630_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/MPG.0b013e318256b516","volume":"55","author":"M Kovacs","year":"2012","unstructured":"Kovacs M, Lakatos PL, Papp M, Jacobsen S, Nemes E, Polgar M et al. Pancreatic Autoantibodies and Autoantibodies Against Goblet Cells in Pediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastr Nutr. 2012;55:429\u2013435.","journal-title":"J Pediatr Gastr Nutr."},{"issue":"10","key":"7630_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/01.MIB.0000182872.76434.8c","volume":"11","author":"IC Lawrance","year":"2005","unstructured":"Lawrance IC, Hall A, Leong R, Pearce C, Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflammatory Bowel Diseases. 2005;11:890\u2013897.","journal-title":"Inflammatory Bowel Diseases."},{"issue":"6","key":"7630_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00054725-200411000-00012","volume":"10","author":"S Joossens","year":"2004","unstructured":"Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflammatory Bowel Diseases. 2004;10:771\u2013777.","journal-title":"Inflammatory Bowel Diseases."},{"issue":"8","key":"7630_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjv087","volume":"9","author":"M Papp","year":"2015","unstructured":"Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z et al. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn\u2019s Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. J Crohns Colitis. 2015;9:659\u2013668.","journal-title":"J Crohns Colitis."},{"key":"7630_CR15","doi-asserted-by":"crossref","unstructured":"Hoie O, Aamodt G, Vermeire S, Bernklev T, Odes S, Wolters FL, et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. Journal of Crohns & Colitis. 2008;2:114\u201322.","DOI":"10.1016\/j.crohns.2007.10.001"},{"issue":"12","key":"7630_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.13641","volume":"43","author":"RS Choung","year":"2016","unstructured":"Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK et al. Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43:1300\u20131310.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"7630_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/gut.2006.108043","volume":"56","author":"M Ferrante","year":"2007","unstructured":"Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394\u20131403.","journal-title":"Gut."},{"issue":"9","key":"7630_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2004.060228","volume":"54","author":"E Israeli","year":"2005","unstructured":"Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232\u20131236.","journal-title":"Gut."},{"issue":"5","key":"7630_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2012-302717","volume":"62","author":"FD van Schaik","year":"2013","unstructured":"van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62:683\u2013688.","journal-title":"Gut."},{"issue":"1","key":"7630_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","volume":"159","author":"J Torres","year":"2020","unstructured":"Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology. 2020;159:96\u2013104.","journal-title":"Gastroenterology."},{"key":"7630_CR21","doi-asserted-by":"crossref","unstructured":"Norberg M, Wall S, Boman K, Weinehall L. The Vasterbotten Intervention Programme: background, design and implications. Global Health Action. 2010;3.","DOI":"10.3402\/gha.v3i0.4643"},{"issue":"10","key":"7630_CR22","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741\u20132749.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"7630_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u2013753.","journal-title":"Gut."},{"issue":"9","key":"7630_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/MEG.0000000000001816","volume":"32","author":"L Widbom","year":"2020","unstructured":"Widbom L, Ekblom K, Karling P, Hultdin J. Patients developing inflammatory bowel disease have iron deficiency and lower plasma ferritin years before diagnosis: a nested case-control study. Eur J Gastroen Hepat. 2020;32:1147\u20131153.","journal-title":"Eur J Gastroen Hepat."},{"key":"7630_CR25","doi-asserted-by":"crossref","unstructured":"Lundgren D, Widbom L, Hultdin J, Karling P. Preclinical Markers in Inflammatory Bowel Disease. A Nested Case-Control Study. Crohns Colitis 360. 2021 Oct;3(4).","DOI":"10.1093\/crocol\/otab072"},{"issue":"1","key":"7630_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00054725-200102000-00002","volume":"7","author":"S Vermeire","year":"2001","unstructured":"Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families. Inflammatory Bowel Diseases. 2001;7:8\u201315.","journal-title":"Inflammatory Bowel Diseases."},{"issue":"8","key":"7630_CR27","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/j.1572-0241.2001.04043.x","volume":"96","author":"V Annese","year":"2001","unstructured":"Annese V, Andreoli A, Andriulli A, D\u2019Inca R, Gionchetti P, Latiano A et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn\u2019s disease and ulcerative colitis: A GISC study. American Journal of Gastroenterology. 2001;96:2407\u20132412.","journal-title":"American Journal of Gastroenterology."},{"issue":"2","key":"7630_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/003655201750065960","volume":"36","author":"F Seibold","year":"2001","unstructured":"Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroentero. 2001;36:196\u2013201.","journal-title":"Scand J Gastroentero."},{"issue":"3","key":"7630_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/21505594.2016.1247140","volume":"8","author":"HE Hallen-Adams","year":"2017","unstructured":"Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8:352\u2013358.","journal-title":"Virulence."},{"issue":"11","key":"7630_CR30","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1086\/497832","volume":"41","author":"A Enache-Angoulvant","year":"2005","unstructured":"Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: A comprehensive review. Clin Infect Dis. 2005;41:1559\u20131568.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"7630_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3748\/wjg.v12.i2.292","volume":"12","author":"RC Mallant-Hent","year":"2006","unstructured":"Mallant-Hent RC, Mooij M, von Blomberg BME, Linskens RK, van Bodegrave AA, Savelkoul PHM. Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroentero. 2006;12:292\u2013297.","journal-title":"World J Gastroentero."},{"issue":"441","key":"7630_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cca.2014.12.010","volume":"20","author":"P Pavlidis","year":"2015","unstructured":"Pavlidis P, Shums Z, Koutsoumpas AL, Milo J, Papp M, Umemura T et al. Diagnostic and clinical significance of Crohn\u2019s disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clin Chim Acta. 2015;20:176\u2013181.","journal-title":"Clin Chim Acta."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:53:09Z","timestamp":1675842789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7630"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07630-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}